Detalles de la búsqueda
1.
A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM).
Clin Infect Dis
; 77(8): 1102-1110, 2023 10 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-37338158
2.
Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Clin Infect Dis
; 65(7): 1174-1182, 2017 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29126292
3.
Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults.
J Infect Dis
; 208(9): 1375-85, 2013 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23908479
4.
A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR).
Hum Vaccin Immunother
; 20(1): 2321035, 2024 Dec 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38497448
5.
Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors.
Hum Vaccin Immunother
; 19(1): 2177066, 2023 12 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-36864601
6.
Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE).
Vaccine
; 40(9): 1342-1351, 2022 02 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-35039194
7.
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU).
Hum Vaccin Immunother
; 18(1): 1-14, 2022 12 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-34726574
8.
Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY).
Open Forum Infect Dis
; 9(3): ofab605, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35146039
9.
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV.
AIDS
; 36(3): 373-382, 2022 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34750291
10.
A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
Vaccine
; 40(1): 162-172, 2022 01 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34507861
11.
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults agedâ¯≥50â¯years: A randomized phase III trial (PNEU-PATH).
Vaccine
; 39(43): 6422-6436, 2021 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34489128
12.
Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older.
Hum Vaccin Immunother
; 17(8): 2678-2690, 2021 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34019468
13.
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Hum Vaccin Immunother
; 15(3): 540-548, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30427749
14.
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults.
Hum Vaccin Immunother
; 15(3): 530-539, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30648919
15.
Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.
Vaccine
; 34(33): 3875-81, 2016 07 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-27265450
16.
Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects.
Hum Vaccin Immunother
; 12(8): 2142-2147, 2016 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27149114
17.
Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes.
Hum Vaccin Immunother
; 12(8): 2135-2141, 2016 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27002793
18.
A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.
Clin Vaccine Immunol
; 15(2): 314-9, 2008 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-18077611
Resultados
1 -
18
de 18
1
Próxima >
>>